ArticleScientific reports2025
Prognostic value of the advanced lung cancer inflammation index for 28 day mortality in sepsis associated acute kidney injury.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Advanced lung cancer inflammation index is associated with mortality in critically ill patients with acute kidney injury.Clinics (Sao Paulo, Brazil) · 2026Article
- Development and Validation of the Composite Renal-Inflammatory-Nutritional-Metabolic Index for Predicting 28-Day Mortality in Critically Ill Patients.Diagnostics (Basel, Switzerland) · 2026Article
- Prognostic significance of the advanced lung cancer inflammation index for long-term mortality in patients with acute myocardial infarction and diabetes.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Sepsis-associated acute kidney injury (SA-AKI) is highly heterogeneous in critically ill patients. Reliable tools that integrate multiple indicators to predict outcomes remain limited. The advanced lung cancer inflammation index (ALI), a composite marker reflecting both inflammation and nutritional status, has demonstrated prognostic value in oncology and chronic diseases. However, evidence for its predictive performance and clinical utility in SA-AKI is scarce and requires further validation. This study analyzed 5,565 SA-AKI patients from the MIMIC-IV 3.1 database. Patients were divided into quartiles based on the ALI. The primary outcomes were 28-day and 90-day all-cause mortality. Multivariate Cox proportional hazards models, Kaplan–Meier survival analysis, and restricted cubic spline models were used to explore associations between the ALI and patient outcomes. Subgroup and sensitivity analyses were performed to test consistency and robustness. ROC analysis was used to compare the discriminatory performance of ALI with other indices and assess its incremental value in existing models. Patients in the highest ALI quartile had significantly lower risks of 28-day (HR = 0.72, p < 0.0001) and 90-day (HR = 0.74, p < 0.0001) mortality than did those in the lowest quartile. Survival curves indicated a strong positive association between the ALI and cumulative survival (log-rank p < 0.0001), and RCS analysis suggested a nonlinear trend. Subgroup analyses revealed no substantial heterogeneity, and sensitivity analyses supported the stability of these associations. ROC analysis demonstrated ALI had superior discrimination for 28-day mortality and provided incremental prognostic value when integrated into the SOFA score. ALI is independently associated with 28-day and 90-day mortality in SA-AKI. It offers incremental prognostic value beyond established scores and may serve as a supplementary risk stratification tool, but validation in prospective multicenter cohorts is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.